Humalog Dosage/Direction for Use

Posology: The dosage should be determined by the physician, according to the requirement of the patient.
Insulin lispro (Humalog KwikPen) may be given shortly before meals. When necessary Insulin lispro (Humalog KwikPen) can be given soon after meals.
Insulin lispro (Humalog KwikPen) takes effect rapidly and has a shorter duration of activity (2 to 5 hours) given subcutaneously as compared with regular insulin. This rapid onset of activity allows Insulin lispro (Humalog KwikPen) injection (or, in the case of administration by continuous subcutaneous infusion, an Insulin lispro [Humalog] bolus) to be given very close to mealtime. The time course of action of any insulin may vary considerably in different individuals or at different times in the same individual. The faster onset of action compared to soluble human insulin is maintained regardless of injection site. As with all insulin preparations, the duration of action of Insulin lispro (Humalog KwikPen) is dependent on dose, site of injection, blood supply, temperature, and physical activity.
Insulin lispro (Humalog KwikPen) can be used in conjunction with a longer-acting human insulin or oral sulphonylurea agents, on the advice of a physician.
Special populations: Renal impairment: Insulin requirements may be reduced in the presence of renal impairment.
Hepatic impairment: Insulin requirements may be reduced in patients with hepatic impairment due to reduced capacity for gluconeogenesis and reduced insulin breakdown; however, in patients with chronic hepatic impairment, an increase in insulin resistance may lead to increased insulin requirements.
Paediatric population: Insulin lispro (Humalog) can be used in adolescents and children (see Pharmacology: Pharmacodynamics under Actions).
Method of administration: Subcutaneous use: Insulin lispro (Humalog KwikPen) preparations should be given by subcutaneous injection. Subcutaneous administration should be in the upper arms, thighs, buttocks, or abdomen. Use of injection sites should be rotated so that the same site is not used more than approximately once a month, in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see Precautions and Adverse Reactions).
When administered subcutaneously care should be taken when injecting Insulin lispro (Humalog KwikPen) to ensure that a blood vessel has not been entered. After injection, the site of injection should not be massaged. Patients must be educated to use the proper injection techniques.
The Insulin lispro (Humalog KwikPen) 100 units/mL delivers 1 - 60 units in steps of 1 unit in a single injection. The number of insulin units is shown in the dose window of the pen.
Intravenous administration of insulin: If necessary, insulin lispro (Humalog KwikPen) may also be administered intravenously, for example; for the control of blood glucose levels during ketoacidosis, acute illnesses or during intra and postoperative periods.
Intravenous injection of insulin lispro should be carried out following normal clinical practice for intravenous injections, for example by an intravenous bolus or by an infusion system. Frequent monitoring of the blood glucose levels is required.
Infusion systems at concentrations from 0.1 units/ml to 1.0 units/ml insulin lispro in 0.9% sodium chloride or 5% dextrose are stable at room temperature for 48 hours. It is recommended that the system is primed before starting the infusion to the patient.